z-logo
open-access-imgOpen Access
Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?
Author(s) -
François Curtin
Publication year - 2014
Publication title -
journal of neurology and neurophysiology
Language(s) - English
Resource type - Journals
ISSN - 2155-9562
DOI - 10.4172/2155-9562.1000197
Subject(s) - alemtuzumab , multiple sclerosis , medicine , neuroscience , omics , computational biology , bioinformatics , immunology , computer science , biology , antibody

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here